Omnicell, Inc. (NASDAQ:OMCL) Stock Position Decreased by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. trimmed its stake in Omnicell, Inc. (NASDAQ:OMCL) by 12.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,977 shares of the company’s stock after selling 1,334 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Omnicell were worth $338,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Gotham Asset Management LLC raised its holdings in Omnicell by 4.7% during the 3rd quarter. Gotham Asset Management LLC now owns 8,120 shares of the company’s stock worth $366,000 after buying an additional 368 shares during the period. Strs Ohio lifted its position in shares of Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock valued at $188,000 after acquiring an additional 1,100 shares in the last quarter. Diversified Trust Co boosted its stake in Omnicell by 10.2% in the 4th quarter. Diversified Trust Co now owns 12,544 shares of the company’s stock worth $472,000 after purchasing an additional 1,162 shares during the period. M&T Bank Corp grew its position in Omnicell by 16.0% during the 4th quarter. M&T Bank Corp now owns 9,570 shares of the company’s stock worth $360,000 after purchasing an additional 1,321 shares in the last quarter. Finally, Arkadios Wealth Advisors raised its stake in Omnicell by 6.2% during the 4th quarter. Arkadios Wealth Advisors now owns 22,985 shares of the company’s stock valued at $865,000 after purchasing an additional 1,341 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Benchmark reaffirmed a “buy” rating and issued a $38.00 target price on shares of Omnicell in a research report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Omnicell currently has an average rating of “Hold” and an average price target of $42.20.

Omnicell Trading Up 3.0 %

NASDAQ OMCL opened at $27.07 on Friday. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48. Omnicell, Inc. has a 1-year low of $25.45 and a 1-year high of $75.07. The firm’s fifty day simple moving average is $29.44 and its 200-day simple moving average is $30.51. The company has a market capitalization of $1.24 billion, a PE ratio of -58.85, a price-to-earnings-growth ratio of 93.16 and a beta of 0.84.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.17. The company had revenue of $246.15 million for the quarter, compared to analyst estimates of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. As a group, sell-side analysts anticipate that Omnicell, Inc. will post 0.2 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.